Julie So-Young Kim Sells 89,090 Shares of Takeda Pharmaceutical (NYSE:TAK) Stock

Takeda Pharmaceutical Co. (NYSE:TAK) CEO Julie So-Young Kim sold 89,090 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $17.10, for a total value of $1,523,439.00. Following the completion of the sale, the chief executive officer owned 391,489 shares of the company’s stock, valued at $6,694,461.90. This trade represents a 18.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Stock Down 0.0%

Shares of TAK stock opened at $17.41 on Friday. Takeda Pharmaceutical Co. has a 1 year low of $12.99 and a 1 year high of $18.90. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.62 and a current ratio of 1.14. The business’s fifty day moving average is $16.53 and its 200-day moving average is $17.14. The stock has a market cap of $55.77 billion, a PE ratio of 51.19 and a beta of -0.08.

Takeda Pharmaceutical (NYSE:TAK) last announced its earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share for the quarter. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%.The business had revenue of $6.90 billion during the quarter. Equities analysts expect that Takeda Pharmaceutical Co. will post 3.01 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Takeda Pharmaceutical

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC raised its holdings in Takeda Pharmaceutical by 14.2% during the 1st quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company’s stock worth $55,358,000 after buying an additional 370,800 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in shares of Takeda Pharmaceutical in the fourth quarter worth about $998,000. Quantinno Capital Management LP increased its position in shares of Takeda Pharmaceutical by 20.6% in the first quarter. Quantinno Capital Management LP now owns 1,289,326 shares of the company’s stock worth $23,878,000 after acquiring an additional 219,999 shares in the last quarter. Bleakley Financial Group LLC increased its position in shares of Takeda Pharmaceutical by 19.0% in the first quarter. Bleakley Financial Group LLC now owns 431,602 shares of the company’s stock worth $7,993,000 after acquiring an additional 68,844 shares in the last quarter. Finally, Sivia Capital Partners LLC acquired a new stake in shares of Takeda Pharmaceutical during the second quarter valued at approximately $351,000. Institutional investors and hedge funds own 9.17% of the company’s stock.

Key Takeda Pharmaceutical News

Here are the key news stories impacting Takeda Pharmaceutical this week:

• Positive Sentiment: The tax-related nature of the transactions reduces their significance as a signal of deteriorating management confidence. Insiders continued to retain substantial positions after selling, including CEO Julie So-Young Kim, who retained 391,489 shares, and Andrew Stewart Plump, who retained 766,569 shares. Takeda insider sales report
• Neutral Sentiment: Analyst views remain mixed, with two Buy ratings, one Hold and one Sell, producing a consensus rating of “Hold.” Institutional ownership is relatively limited at 9.17%, although several funds recently increased their positions. Takeda stock analysis
• Neutral Sentiment: Takeda’s latest reported quarter included $0.56 in EPS and $6.90 billion in revenue. Analysts expect approximately $3.01 in earnings per share for the current year, providing a fundamental backdrop for the stock as it trades near its 12-month high. Takeda financial data
• Negative Sentiment: Multiple insiders sold a combined 444,100 shares for approximately $7.59 million at an average price of $17.10. The sellers included CEO Julie So-Young Kim, General Counsel Natalie Anne Marie Furney, Andrew Stewart Plump and other executives; individual ownership reductions ranged from 5.9% to 18.5%. The volume and seniority of the sellers may weigh on sentiment, even though the sales were made for tax purposes. SEC insider filing

Analysts Set New Price Targets

TAK has been the topic of several recent research reports. Zacks Research raised shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 4th. Weiss Ratings cut shares of Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, July 30th. Finally, Wall Street Zen upgraded shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Takeda Pharmaceutical presently has an average rating of “Hold”.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.